These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Treatment of hyperlipidaemia as a risk factor for coronary heart disease: the role of fibrates. Linssen R Hosp Med; 1999 Apr; 60(4):298-301. PubMed ID: 10396439 [No Abstract] [Full Text] [Related]
24. Combination lipid therapy in type 2 diabetes. Saely CH; Rein P; Drexel H N Engl J Med; 2010 Aug; 363(7):692; author reply 694-5. PubMed ID: 20701533 [No Abstract] [Full Text] [Related]
25. Pharmacologic prevention of coronary artery disease. What do clinical trials show? Milani RV; Lavie CJ Postgrad Med; 1996 Feb; 99(2):109-12, 115-20. PubMed ID: 8632961 [TBL] [Abstract][Full Text] [Related]
26. [Current views on lowering blood cholesterol for prevention of coronary artery diseases]. Zhao S Zhonghua Nei Ke Za Zhi; 2001 May; 40(5):290-2. PubMed ID: 12947967 [No Abstract] [Full Text] [Related]
27. Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult diabetics in Finland. Results from large national database between 2000 and 2006. Ahola TL; Jula AM; Kantola IM; Mäki J; Klaukka T; Reunanen A J Hypertens; 2009 Nov; 27(11):2283-93. PubMed ID: 19834341 [TBL] [Abstract][Full Text] [Related]
28. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: the time is now. Fonarow GC; Ballantyne CM Circulation; 2001 Jun; 103(23):2768-70. PubMed ID: 11401927 [No Abstract] [Full Text] [Related]
29. [Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects]. Demant T Fortschr Med Orig; 2001; 119(1):37-40. PubMed ID: 11935656 [TBL] [Abstract][Full Text] [Related]
30. Lipid-lowering therapy after coronary artery bypass grafting: time for more aggressive intervention. Lucas BD Am J Health Syst Pharm; 2002 Nov; 59(21):2101-3. PubMed ID: 12434726 [No Abstract] [Full Text] [Related]
31. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465 [TBL] [Abstract][Full Text] [Related]
32. [The importance of determining the type of hyperlipidemia for lipotropic therapy of atherosclerosis]. Bavina MV; Perova NV; Lobova NM; Koropova GI Kardiologiia; 1973 Mar; 13(3):27-33. PubMed ID: 4717180 [No Abstract] [Full Text] [Related]
33. Correlation of lipoprotein (a) concentration with the extent of coronary artery disease in patients on lipid lowering therapy. Malek F; Dvorak J; Svitil J; Skalnikova V; Mates M; Kmonicek P; Formanek P; Aschermann O; Kopriva K; Neuzil P Neuro Endocrinol Lett; 2012; 33 Suppl 2():55-9. PubMed ID: 23183511 [TBL] [Abstract][Full Text] [Related]
36. Do lipid-lowering agents provide a greater reduction in cardiovascular events among patients with diabetes? Gollapudi AK Ann Intern Med; 2008 Dec; 149(11):841; author reply 841-2. PubMed ID: 19047040 [No Abstract] [Full Text] [Related]